Covance is augmenting its global capabilities for outsourced biologics development with new investment in facilities and additions to its biologics team.
In its home market, the US-based drug-development services company is filling out its large-molecule bioanalytical space co-located with Covance’s central-laboratory facility in Indianapolis, Indiana.
The expanded facilities, which are scheduled to open during the second half of 2014, will double Covance’s large-molecule capacity and are expected to add some 100 new positions in the segment over the next five years.
The investment will enable Covance further to leverage its small- and large-molecule bioanalytical expertise while providing scientific, logistical and regulatory synergies for its clients, the company said.
Covance has also appointed Mike Holsapple as executive director of global immunotoxicology. Holsapple is a fellow of the US Academy of Toxicological Sciences and a past president of the Society of Toxicology.
In conjunction with this appointment, Covance has launched molecule-management teams of experienced scientific leaders who work closely with the company’s clients to develop and implement tailored solutions for biologics development.
These solutions will leverage Covance’s broad portfolio of services, including product discovery, preclinical testing, early and late clinical trials, central laboratories and commercialisation, the company noted.
“Our new biologics solutions will enable us to work in closer collaboration with our clients, providing them actionable insights to help expedite their large-molecule development,” commented Deborah Keller, executive vice president, R&D Laboratories, at Covance.
“Doubling our large molecule capacity and enhancing a leading team with additional dedicated scientific experts with proven success in managing through these complexities will further strengthen our leadership position in a growing market,” Keller added.